NanoViricides, Inc. (NASDAQ:NNVC)

PRESS RELEASE

published on 11/15/2024 at 12:30, 1 year 4 months ago

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
NanoViricides, Inc. files Quarterly Report on Form 10-Q with the SEC, highlights financial results and progress on NV-387 antiviral drug for various infections including MPox and RSV

NanoViricides NV-387 Quarterly Report SEC Filing Antiviral Drug
BRIEF

published on 11/04/2024 at 06:05, 1 year 4 months ago

NanoViricides Presents at Spartan Capital Investors Conference 2024

NanoViricides NV-387 Antiviral Nanomedicines Spartan Capital Conference Dr. Anil R. Diwan
BRIEF

published on 11/04/2024 at 06:05, 1 year 4 months ago

NanoViricides présente sa nouvelle technologie à la conférence Spartan Capital Investors 2024

NanoViricides NV-387 Nanomédicaments Antiviraux Conférence Sur La Capitale Spartiate Dr Anil R. Diwan
PRESS RELEASE

published on 11/04/2024 at 06:00, 1 year 4 months ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
NanoViricides, Inc. to present corporate update at Spartan Capital Investors Conference on NV-387 antiviral drug development with strong market potential

NV-387 NanoViricides Inc. Market Potential Antiviral Drug Spartan Capital Investors Conference
BRIEF

published on 10/22/2024 at 12:35, 1 year 5 months ago

NanoViricides President to Present at PODD Conference

NanoViricides NV-387 Drug Delivery PODD Conference Antiviral Treatments
BRIEF

published on 10/22/2024 at 12:35, 1 year 5 months ago

Le président de NanoViricides fera une présentation à la conférence PODD

NanoViricides NV-387 Administration De Médicaments Conférence PODD Traitements Antiviraux
PRESS RELEASE

published on 10/22/2024 at 12:30, 1 year 5 months ago

NanoViricides President Dr. Diwan to Present at the PODD Conference
NanoViricides announces President Dr. Anil R. Diwan to speak at PODD Conference about revolutionary antiviral nanomedicines. Conference focuses on drug delivery partnerships and trends

NanoViricides Drug Delivery Antiviral Nanomedicines PODD Conference Anil R. Diwan
BRIEF

published on 10/15/2024 at 12:35, 1 year 5 months ago

Innovative Antiviral Technology Discussed in Recent NanoViricides Podcast

NanoViricides NV-387 Antiviral Treatment Phase II Trials Nanomedicine Technology
BRIEF

published on 10/15/2024 at 12:35, 1 year 5 months ago

Une technologie antivirale innovante évoquée dans le récent podcast NanoViricides

NanoViricides NV-387 Traitement Antiviral Essais De Phase II Technologie De La Nanomédecine
PRESS RELEASE

published on 10/15/2024 at 12:30, 1 year 5 months ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
NanoViricides, Inc. announces interview with Dr. Diwan discussing revolutionary broad-spectrum antiviral clinical drug candidate NV-387 and innovative nanoviricide technology platform

NV-387 Clinical Trials NanoViricides Inc. Antiviral NanoViricides Technology

Published on 03/26/2026 at 21:00, 1 hour 1 minute ago

Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 21:00, 1 hour 1 minute ago

Rocky Shore Closes Acquisition of Additional Mining Claims
Published on 03/26/2026 at 16:20, 5 hours 41 minutes ago

ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 14:05, 7 hours 56 minutes ago

SouthGobi Announces Profit Warning
Published on 03/26/2026 at 13:00, 9 hours 1 minute ago

Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor

View all ACCESSWIRE

Published on 03/26/2026 at 20:48, 1 hour 12 minutes ago

Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 2 hours 40 minutes ago

Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:13, 2 hours 47 minutes ago

Director Declaration
Published on 03/26/2026 at 19:09, 2 hours 51 minutes ago

2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 2 hours 51 minutes ago

2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)

View all EQS

Published on 03/26/2026 at 18:17, 3 hours 44 minutes ago

Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 3 hours 44 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 4 hours 1 minute ago

Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 4 hours 1 minute ago

Calendrier financier 2026
Published on 03/26/2026 at 18:00, 4 hours 1 minute ago

LABORATOIRES EUROMEDIS - Fin du contrat de liquidité

View all LES ECHOS COMFI WIRE

News